Baidu
map

默沙东丙肝鸡尾酒MK-5172/MK-8742初治群体治愈率近100%

2014-04-11 tomato 生物谷

默沙东(Merck & Co)4月10日公布了一项正在开展的II期研究(C-WORTHY Study)的额外数据。对初治非肝硬化患者组开展的一项中期分析表明,接受为期12周的MK-5127/MK-8742方案(联合利巴韦林RBV及无RBV)治疗后,MK-5127/MK-8742(无RBV)治疗组有98%(42/43)的患者取得持续病毒学应答(SVR),MK-5127/MK-8742+RBV

默沙东(Merck & Co)4月10日公布了一项正在开展的II期研究(C-WORTHY Study)的额外数据。对初治非肝硬化患者组开展的一项中期分析表明,接受为期12周的MK-5127/MK-8742方案(联合利巴韦林RBV及无RBV)治疗后,MK-5127/MK-8742(无RBV)治疗组有98%(42/43)的患者取得持续病毒学应答(SVR),MK-5127/MK-8742+RBV治疗组为94%(75/80)。这些数据连同8周方案的数据已提交至第49届欧洲肝脏研究协会年会(EASL 2014-49th)。

MK-5172和MK-8742均属于非常有前途的新一类抗病毒药物。MK-5172是一种实验性HCV NS3/4A蛋白酶抑制剂,MK-8742则是一种实验性HCV NS5A复制复合体抑制剂。此前,FDA于2013年10月授予MK-5172/MK-8742全口服方案突破性疗法认定。

慢性丙型肝炎是默沙东研发的优先重点。目前,该公司正在一个广泛的临床项目中评价MK-5172和MK-8742,包括多种HCV基因型感染初治患者、治疗失败的患者、以及其他重要的HCV亚群,如肝硬化和HCV/HIV合并感染。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=17103, encodeId=cc221e1033d, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 15:35:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988731, encodeId=a8301988e318d, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Oct 15 19:27:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716926, encodeId=71211e169269c, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Sat Mar 21 17:27:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259902, encodeId=f81b125990271, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574786, encodeId=489e15e47863c, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2015-02-27 xiaoai5777

    不错的文章,学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=17103, encodeId=cc221e1033d, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 15:35:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988731, encodeId=a8301988e318d, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Oct 15 19:27:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716926, encodeId=71211e169269c, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Sat Mar 21 17:27:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259902, encodeId=f81b125990271, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574786, encodeId=489e15e47863c, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2014-10-15 cenghis
  3. [GetPortalCommentsPageByObjectIdResponse(id=17103, encodeId=cc221e1033d, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 15:35:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988731, encodeId=a8301988e318d, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Oct 15 19:27:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716926, encodeId=71211e169269c, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Sat Mar 21 17:27:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259902, encodeId=f81b125990271, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574786, encodeId=489e15e47863c, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2015-03-21 xjy13
  4. [GetPortalCommentsPageByObjectIdResponse(id=17103, encodeId=cc221e1033d, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 15:35:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988731, encodeId=a8301988e318d, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Oct 15 19:27:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716926, encodeId=71211e169269c, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Sat Mar 21 17:27:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259902, encodeId=f81b125990271, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574786, encodeId=489e15e47863c, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2014-04-13 yese
  5. [GetPortalCommentsPageByObjectIdResponse(id=17103, encodeId=cc221e1033d, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 15:35:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1988731, encodeId=a8301988e318d, content=<a href='/topic/show?id=fada6455e8c' target=_blank style='color:#2F92EE;'>#治愈率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64557, encryptionId=fada6455e8c, topicName=治愈率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Oct 15 19:27:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716926, encodeId=71211e169269c, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Sat Mar 21 17:27:00 CST 2015, time=2015-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259902, encodeId=f81b125990271, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103360, encryptionId=6ff910336054, topicName=默沙东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574786, encodeId=489e15e47863c, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Sun Apr 13 00:27:00 CST 2014, time=2014-04-13, status=1, ipAttribution=)]
    2014-04-13 qblt

相关资讯

FDA授予诺华脑膜炎疫苗Bexsero突破性疗法认定

诺华(Novartis)4月7日宣布,FDA已授予B型脑膜炎球菌疫苗Bexsero突破性疗法认定。目前,Bexsero已获欧盟、加拿大、澳大利亚批准,用于年龄在2个月以上的人群。Bexsero是首个也是唯一一个宽覆盖范围的B型脑膜炎球菌疫苗,用于帮助保护所有年龄段人群预防B型脑膜炎,包括婴儿。 诺华计划于2014年第二季度向FDA提交Bexsero的监管文件。这是诺华获得的第4个突破性疗法认定,

百时美丙肝鸡尾酒疗法DCV/ASV III期治愈率达90%

百时美施贵宝(BMS)4月10日公布了丙肝鸡尾酒疗法(daclatasvir+asunaprevir,即DCV+ASV)一项国际性III期研究HALLMARK-DUAL的数据。DCV+ASV是一种实验性全口服、无干扰素、无利巴韦林丙肝治疗方案。该项研究在基因型1b丙型肝炎病毒(HCV)感染者中开展,数据表明,接受DCV+ASV方案治疗后,初治患者组有90%的患者实现SVR12(完成治疗后12周的持

安进黑色素瘤溶瘤免疫疗法T-Vec III期未改善总生存期

安进(Amgen)4月5日公布了实验性溶瘤免疫疗法talimogene laherparepvec(T-Vec)黑色素瘤关键性III期研究的总生存期(OS)初步分析数据。该项研究在可注射未切除IIIB、IIIC、IV期黑色素瘤(melanoma)患者中开展,将T-Vec疗法与皮下注射粒细胞-巨噬细胞集落刺激因子(GM-CSF)疗法进行了对比。数据表明,该项研究达到了持久反应率(DRR)的主要终点(

以CDK4/6为靶点的三种乳腺癌新药均取得不俗进展 能延长晚期乳癌患者生命

肿瘤新药以及新靶点药物研究成为热点领域。其中针对CDK4/6的乳腺癌新药成为新的竞争焦点。以辉瑞,礼来和诺华三家公司为代表的新药palbociclib,LY2835219和LEE011引发广泛关注。今年的美国癌症研究学会年会上,礼来公司的CDK4/6抑制剂类药物LY2835219引起了业界的广泛关注。礼来公司表示,目前研究人员正在进行这种药物的三期临床研究实验设计,相信很快就能进入三期研究阶段。近

勃林格殷格翰抗凝血剂Pradaxa新适应症获FDA批准

勃林格殷格翰(Boehringer Ingelheim)4月7日宣布,FDA已批准Pradaxa(dabigatran,达比加群酯)用于已接受5-10天肠外抗凝剂(parenteral anticoagulant)的患者,治疗深静脉血栓(DVT)和肺栓塞(PE),以及用于既往已治疗过的患者,降低DVT和PE复发的风险。 深静脉血栓(DVT)和肺栓塞(PE)统称为静脉血栓栓塞(VTE),是继冠状动

Puma制药neratinib用于HER2阳性乳腺癌疗效优于罗氏赫赛汀

Puma生物技术公司4月7日公布了抗癌药neratinib(来那替尼)一项II期研究(I-SPY 2)的数据。该项研究在193例术前新诊具有高复发风险(根据前期肿瘤属性判断,包括肿瘤大小、激素受体HR状态、HER2状态、MammaPrint-70基因指纹检测)的2阶段或更晚阶段(肿瘤至少2.5cm)的乳腺癌患者开展,调查了将neratinib添加至标准化疗用于新辅助治疗(neoadjuvant s

Baidu
map
Baidu
map
Baidu
map